Highlights Tourmaline Bio, Inc.

Equities

TRML

US89157D1054

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-29 pm EDT			5-day change	1st Jan Change
15.5 ^USD	-1.15%		+2.72%	-40.79%

Apr. 25	Certain Restricted Stock Units of Tourmaline Bio, Inc. are subject to a Lock-Up Agreement Ending on 25-APR-2024.	CI
Apr. 25	Certain Options of Tourmaline Bio, Inc. are subject to a Lock-Up Agreement Ending on 25-APR-2024.	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Top Premarket Decliners	Mar. 21	MT
Tourmaline Reports Q4 Net Loss; Cash to Fund Operations Until 2027	Mar. 19	MT
Tourmaline Bio, Inc. Plans to Commence a Phase 2 Trial Evaluating Quarterly Subcutaneous Dosing of TOUR006 in Patients with Elevated Cardiovascular Risk in the First Half of 2024	Mar. 19	CI
Tourmaline Bio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 19	CI
Tourmaline Bio, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 19	CI
Talaris Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 14	CI
Tourmaline Bio Closes Merger With Talaris Therapeutics	23-10-20	MT
Tourmaline Bio Completes Merger With Talaris Therapeutics	23-10-19	MT
Tourmaline Bio, Inc. completed the acquisition of Talaris Therapeutics, Inc. from a group of shareholders in a reverse merger transaction.	23-10-18	CI
Talaris Therapeutics Shareholders OK Merger With Tourmaline Bio	23-10-18	MT
Talaris Therapeutics, Inc. Announces Special Dividend	23-10-06	CI
Talaris Therapeutics Sells Tolerance Business to ImmunoFree	23-08-14	MT
Talaris Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14	CI
Aquila European says no hit from Siemens Energy woe	23-06-30	AN
Talaris Therapeutics to Merge With Tourmaline Bio in All-Stock Deal	23-06-22	MT
Tourmaline Bio, Inc. entered into a definitive agreement to acquire Talaris Therapeutics, Inc. from shareholders in a reverse merger transaction.	23-06-21	CI
Talaris Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-15	CI
TALARIS THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-K)	23-03-31	AQ
Talaris Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-31	CI
Talaris Therapeutics, Inc. Announces Plans to Explore Strategic Alternatives and Implements Restructuring Plan	23-02-16	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Tourmaline Bio, Inc.

Equities

TRML

US89157D1054

Highlights

Filters